Wall Street analyst estimates for Abivax S.A. (ABVX): consensus price target and buy/hold/sell recommendations.
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19.
Consensus price target
$156.00 (+76 % vs price $88.71)
between $118.00 and $180.00 · 3 targets published in the last quarter
Closing price, Nov 3
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 12 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 13 |
| Avg rating (−2 sell to +2 buy) | 0.92 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-12-21 | $-0.92 | ||
| 2026-09-21 | $-1.71 | $-0.98 | -75.3% |
| 2026-05-22 | $-0.71 | $-1.07 | +33.6% |
| 2026-03-23 | $-1.19 | $-1.70 | +30.0% |
| 2025-12-15 | $-2.47 | $-0.79 | -214.3% |
| 2025-09-08 | $-0.86 | $-0.90 | +4.4% |
| 2025-06-02 | $-0.97 | $-0.76 | -28.3% |
| 2025-03-24 | $-1.68 | $-1.59 | -5.8% |
Valuation Ratios
| Price / Book | 17.28 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127,000 EUR | 10,000 EUR | 18,000 EUR | 2,000 EUR | 63,000 EUR | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 14.6M EUR | 14.5M EUR | 15.4M EUR | 28.2M EUR | 33.8M EUR | 45.5M EUR | 50.8M EUR | 0 | 0 | 0 |
| Gross Profit | -14.5M EUR | -14.5M EUR | -15.4M EUR | -28.2M EUR | -33.8M EUR | -45.5M EUR | -50.8M EUR | 0 | 0 | 0 |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 47.8M EUR | 48.3M EUR | 103.2M EUR | 146.5M EUR | 177.8M EUR |
| Selling, General & Admin | 3.6M EUR | 3.8M EUR | 4.3M EUR | 4.9M EUR | 5.6M EUR | 5.6M EUR | 7.5M EUR | 28.8M EUR | 38.9M EUR | 72.9M EUR |
| Operating Expenses | 3.7M EUR | -347,000 EUR | 3.7M EUR | 5.1M EUR | 4.2M EUR | -4.1M EUR | 14.1M EUR | 127.4M EUR | 173.0M EUR | 246.1M EUR |
| Operating Income | -18.2M EUR | -14.2M EUR | -19.1M EUR | -33.3M EUR | -38.0M EUR | -41.4M EUR | -64.8M EUR | -127.4M EUR | -173.0M EUR | -246.1M EUR |
| EBITDA | -17.9M EUR | -14.0M EUR | -19.2M EUR | -33.2M EUR | -38.0M EUR | -38.6M EUR | -53.3M EUR | -133.2M EUR | -162.7M EUR | -300.7M EUR |
| Interest Expense | 42,000 EUR | 0 | 469,000 EUR | 1.6M EUR | 2.1M EUR | 3.6M EUR | 6.9M EUR | 13.8M EUR | 12.4M EUR | 28.5M EUR |
| Pre-tax Income | -18.0M EUR | -14.1M EUR | -19.8M EUR | -34.9M EUR | -40.1M EUR | -42.5M EUR | -60.7M EUR | -147.7M EUR | -176.2M EUR | -330.3M EUR |
| Income Tax | -3.5M EUR | -2.7M EUR | -4.0M EUR | -4.3M EUR | -2.6M EUR | 0 | 0 | 0 | 0 | 5.8M EUR |
| Net Income | -14.3M EUR | -11.2M EUR | -15.8M EUR | -30.6M EUR | -37.6M EUR | -42.5M EUR | -60.7M EUR | -147.7M EUR | -176.2M EUR | -336.1M EUR |
| EPS | -€1.48 | -€1.14 | -€1.56 | -€2.51 | -€2.62 | -€2.75 | -€3.18 | -€3.43 | -€2.80 | -€4.65 |
| EPS (Diluted) | -€1.47 | -€1.13 | -€1.55 | -€2.51 | -€2.62 | -€2.75 | -€3.18 | -€3.43 | -€2.80 | -€4.65 |
| Shares Outstanding (Diluted) | 9.7 M | 9.9 M | 10.2 M | 12.2 M | 14.3 M | 15.5 M | 19.1 M | 43.1 M | 63.0 M | 69.5 M |
Price
| Price | $88.71 (closing price, November 3, 2026) |
| Market Cap | $7.8B |
| Exchange | NASDAQ |
| Country | FR |
Related companies: SYRE · NRIX · RCUS · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of ABVX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks